111 related articles for article (PubMed ID: 33243603)
1. A novel target anti-interleukin-13 receptor subunit alpha-2 monoclonal antibody inhibits tumor growth and metastasis in lung cancer.
Raza G; Yunus FU; Mangukiya HB; Merugu SB; Mashausi DS; Zeling W; Negi H; Zhou B; Roy D; Wu Z; Li D
Int Immunopharmacol; 2021 Jan; 90():107155. PubMed ID: 33243603
[TBL] [Abstract][Full Text] [Related]
2. An IL13Rα2 peptide exhibits therapeutic activity against metastatic colorectal cancer.
Bartolomé RA; Jaén M; Casal JI
Br J Cancer; 2018 Oct; 119(8):940-949. PubMed ID: 30318506
[TBL] [Abstract][Full Text] [Related]
3. IL-13 receptor α2 is a negative prognostic factor in human lung cancer and stimulates lung cancer growth in mice.
Xie M; Wu XJ; Zhang JJ; He CS
Oncotarget; 2015 Oct; 6(32):32902-13. PubMed ID: 26418721
[TBL] [Abstract][Full Text] [Related]
4. Characterization and immunotherapeutic implications for a novel antibody targeting interleukin (IL)-13 receptor α2.
Balyasnikova IV; Wainwright DA; Solomaha E; Lee G; Han Y; Thaci B; Lesniak MS
J Biol Chem; 2012 Aug; 287(36):30215-27. PubMed ID: 22778273
[TBL] [Abstract][Full Text] [Related]
5. A novel single-chain antibody redirects adenovirus to IL13Rα2-expressing brain tumors.
Kim JW; Young JS; Solomaha E; Kanojia D; Lesniak MS; Balyasnikova IV
Sci Rep; 2015 Dec; 5():18133. PubMed ID: 26656559
[TBL] [Abstract][Full Text] [Related]
6. Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants.
Krenciute G; Prinzing BL; Yi Z; Wu MF; Liu H; Dotti G; Balyasnikova IV; Gottschalk S
Cancer Immunol Res; 2017 Jul; 5(7):571-581. PubMed ID: 28550091
[TBL] [Abstract][Full Text] [Related]
7. Differential expression of the alpha2 chain of the interleukin-13 receptor in metastatic human prostate cancer ARCaPM cells.
He H; Xu J; Nelson PS; Marshall FF; Chung LW; Zhau HE; He D; Wang R
Prostate; 2010 Jun; 70(9):993-1001. PubMed ID: 20166133
[TBL] [Abstract][Full Text] [Related]
8. A novel ligand delivery system to non-invasively visualize and therapeutically exploit the IL13Rα2 tumor-restricted biomarker.
Nguyen V; Conyers JM; Zhu D; Gibo DM; Hantgan RR; Larson SM; Debinski W; Mintz A
Neuro Oncol; 2012 Oct; 14(10):1239-53. PubMed ID: 22952195
[TBL] [Abstract][Full Text] [Related]
9. Targeting and pharmacology of an anti-IL13Rα2 antibody and antibody-drug conjugate in a melanoma xenograft model.
Gupta P; Jiang ZK; Yang B; Manzuk L; Rosfjord E; Yao J; Lemon L; Noorbehesht K; David J; Puthenveetil S; Casavant JM; Muszynska E; Li F; Leal M; Sapra P; Giddabasappa A
MAbs; 2021; 13(1):1958662. PubMed ID: 34347577
[TBL] [Abstract][Full Text] [Related]
10. Targeting IL13Ralpha2 activates STAT6-TP63 pathway to suppress breast cancer lung metastasis.
Papageorgis P; Ozturk S; Lambert AW; Neophytou CM; Tzatsos A; Wong CK; Thiagalingam S; Constantinou AI
Breast Cancer Res; 2015 Jul; 17(1):98. PubMed ID: 26208975
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-13 receptor alpha2 is a novel therapeutic target for human adrenocortical carcinoma.
Jain M; Zhang L; He M; Patterson EE; Nilubol N; Fojo AT; Joshi B; Puri R; Kebebew E
Cancer; 2012 Nov; 118(22):5698-708. PubMed ID: 22570059
[TBL] [Abstract][Full Text] [Related]
12. Cytokine induction of VCAM-1 but not IL13Rα2 on glioma cells: a tale of two antibodies.
Mahadev V; Starr R; Wright SL; Martinez C; Jensen MC; Barish ME; Forman SJ; Brown CE
PLoS One; 2014; 9(5):e95123. PubMed ID: 24787244
[TBL] [Abstract][Full Text] [Related]
13. Characterization and Functional Analysis of scFv-based Chimeric Antigen Receptors to Redirect T Cells to IL13Rα2-positive Glioma.
Krenciute G; Krebs S; Torres D; Wu MF; Liu H; Dotti G; Li XN; Lesniak MS; Balyasnikova IV; Gottschalk S
Mol Ther; 2016 Feb; 24(2):354-363. PubMed ID: 26514825
[TBL] [Abstract][Full Text] [Related]
14. T cells redirected to interleukin-13Rα2 with interleukin-13 mutein--chimeric antigen receptors have anti-glioma activity but also recognize interleukin-13Rα1.
Krebs S; Chow KK; Yi Z; Rodriguez-Cruz T; Hegde M; Gerken C; Ahmed N; Gottschalk S
Cytotherapy; 2014 Aug; 16(8):1121-31. PubMed ID: 24841514
[TBL] [Abstract][Full Text] [Related]
15. Targeting metastatic breast cancer with peptide epitopes derived from autocatalytic loop of Prss14/ST14 membrane serine protease and with monoclonal antibodies.
Kim KY; Yoon M; Cho Y; Lee KH; Park S; Lee SR; Choi SY; Lee D; Yang C; Cho EH; Jeon SD; Kim SH; Kim C; Kim MG
J Exp Clin Cancer Res; 2019 Aug; 38(1):363. PubMed ID: 31426843
[TBL] [Abstract][Full Text] [Related]
16. Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma.
Pituch KC; Miska J; Krenciute G; Panek WK; Li G; Rodriguez-Cruz T; Wu M; Han Y; Lesniak MS; Gottschalk S; Balyasnikova IV
Mol Ther; 2018 Apr; 26(4):986-995. PubMed ID: 29503195
[TBL] [Abstract][Full Text] [Related]
17. IL13Rα2-targeted third-generation CAR-T cells with CD28 transmembrane domain mediate the best anti-glioblastoma efficacy.
Gu A; Bai Y; Zhang C; Xu C; An Z; Zhang Y; Zhong SH; Hu Y; Zhong X
Cancer Immunol Immunother; 2023 Jul; 72(7):2393-2403. PubMed ID: 36991262
[TBL] [Abstract][Full Text] [Related]
18. Stem-like tumor-initiating cells isolated from IL13Rα2 expressing gliomas are targeted and killed by IL13-zetakine-redirected T Cells.
Brown CE; Starr R; Aguilar B; Shami AF; Martinez C; D'Apuzzo M; Barish ME; Forman SJ; Jensen MC
Clin Cancer Res; 2012 Apr; 18(8):2199-209. PubMed ID: 22407828
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-13 receptor α2 is a novel marker and potential therapeutic target for human melanoma.
Okamoto H; Yoshimatsu Y; Tomizawa T; Kunita A; Takayama R; Morikawa T; Komura D; Takahashi K; Oshima T; Sato M; Komai M; Podyma-Inoue KA; Uchida H; Hamada H; Fujiu K; Ishikawa S; Fukayama M; Fukuhara T; Watabe T
Sci Rep; 2019 Feb; 9(1):1281. PubMed ID: 30718742
[TBL] [Abstract][Full Text] [Related]
20. Anterior Gradient-2 monoclonal antibody inhibits lung cancer growth and metastasis by upregulating p53 pathway and without exerting any toxicological effects: A preclinical study.
Negi H; Merugu SB; Mangukiya HB; Li Z; Zhou B; Sehar Q; Kamle S; Yunus FU; Mashausi DS; Wu Z; Li D
Cancer Lett; 2019 May; 449():125-134. PubMed ID: 30685412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
